Curevac AG, of Tubingen, Germany, and the Coalition for Epidemic Preparedness Innovations (CEPI) are collaborating to develop an mRNA-based vaccine against coronavirus nCoV-2019. CEPI is contributing $8.3 million for development, manufacturing and clinical trials.
Follicum AB, of Lund, Sweden, was awarded a SEK500,000 (US$51,800) grant from Vinnova to study binding of FOL peptides to receptors on pancreatic cells. Lund University and Saromics Biostructures AB, of Lund, will also be involved with the 1.5-year project.
Fuzionaire Diagnostics Inc., of Pasadena, Calif., is collaborating with McGill University and The Neuro to develop new ways to detect and treat neurodegenerative diseases. The collaboration will use Fuzionaire's radiochemistry platform to develop radiopharmaceuticals that localize in the brain to be used as non-invasive diagnostic imaging tests for Alzheimer’s disease, Parkinson’s disease and traumatic brain injury. The collaboration will also explore development of therapies against neurodegenerative disease.
Nanoviricides Inc., of Shelton, Conn., is developing a treatment for coronavirus 2019-nCoV by targeting the cell surface receptor ACE2.
Novartis AG, of Basel, Switzerland, completed the acquisition of the Japanese business of Aspen Global Inc., a unit of Durban, South Africa-based Aspen Pharmacare Holdings Ltd. Novartis' Sandoz unit acquired all of the shares in Aspen Japan K.K. and associated assets held by Aspen for an undisclosed amount. Through the acquisition, Sandoz gains access to approximately 20 products of off-patent medicines.
Predictive Oncology Inc., of Minneapolis, said it signed a letter of intent to acquire Quantitative Medicine LLC, of Pittsburgh, in a deal that will add the latter’s Core predictive modeling platform and tumor profiling expertise and data. Predictive Oncology intends to integrate its artificial intelligence data with Core to build predictive models of how specific types of tumors will react to cancer drug therapies. The deal is set to close in the first quarter. Financial terms were not disclosed.
The Institute for Clinical and Economic Review, of Boston, updated the value assessment framework that will guide future assessments. Changes include increasing the use of real-world evidence, a revised voting structure, adding evidence on heterogeneity and subgroups, standardizing cost-effectiveness thresholds, incorporating societal costs, reassessments after one year and increasing patient input.
Vaxart Inc., of South San Francisco, is developing a vaccine for coronavirus 2019-nCoV based on its oral vaccine platform.
Ziopharm Oncology Inc., of Boston, published results from a study of peripheral blood lymphocytes (PBL) from patients with mutated TP53 tumors in Clinical Cancer Research. Five patients with tumor-infiltrating lymphocyte (TIL) responses to mutated TP53 had responses in their PBLs. Responses in PBLs weren't seen in the four patients who didn't have TIL responses.